Enanta Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-61.98	-81.89	-116.05	-133.82	-121.76	-79
Depreciation & Amortization	4.93	4.59	2.34	2.37	2.97	3.33
Stock-Based Compensation	15.77	18.57	26.8	28.22	26.97	20.99
Other Adjustments	-1.27	-0.44	1.02	-7.95	0.24	-1.64
Change in Receivables	-1.02	-0.24	1.97	11.7	3.26	-0.08
Changes in Accounts Payable	0.4	-1.31	-0.41	-1.15	-4.63	3.77
Changes in Accrued Expenses	-0.95	0.06	-5.65	-2.56	-1.48	8.35
Changes in Other Operating Activities	36.32	41.4	11.22	0.03	9.64	-25.73
Operating Cash Flow	-7.84	-19.27	-78.76	-103.15	-84.78	-70
Capital Expenditures	-1.77	-12.9	-17.95	-9.06	-2.13	-0.75
Purchases of Investments	-345.19	-209.63	-307.28	-373.39	-171.45	-307.35
Proceeds from Sale of Investments	287.42	262.87	383.47	328.87	228.47	345.09
Investing Cash Flow	-59.54	40.35	58.24	-53.58	54.9	36.99
Long-Term Debt Issued	-	-	-	200	-	-
Long-Term Debt Repaid	-27.68	-26.49	-27.48	-	-	-
Net Long-Term Debt Issued (Repaid)	-27.68	-26.49	-27.48	200	-	-
Issuance of Common Stock	70.19	0.15	0.15	2.21	21.26	3.61
Repurchase of Common Stock	-0.42	-0.28	-0.29	-3.76	-1.23	-0.53
Net Common Stock Issued (Repurchased)	69.77	-0.13	-0.15	-1.55	20.03	3.08
Other Financing Activities	-	-	-	-0.33	-	-
Financing Cash Flow	42.1	-26.62	-27.63	198.13	20.03	3.08
Net Cash Flow	-25.29	-5.54	-48.16	41.39	-9.85	-29.93
Free Cash Flow	-9.61	-32.17	-96.71	-112.21	-86.91	-70.75
FCF Margin	-13.88%	-49.24%	-142.99%	-141.67%	-100.87%	-72.88%
Free Cash Flow Per Share	-0.38	-1.51	-4.57	-5.35	-4.22	-3.51
Levered Free Cash Flow	-50.73	-76.54	-153.97	55.82	-117.38	-90.02
Unlevered Free Cash Flow	-21.54	-51.82	-130.34	-150.53	-119.03	-91.48

SEC Filings: 10-K · 10-Q